MarketBeat
17 Nov 2026, 03:12 UTC · 1h ago
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
Impact · against what's priced in
United Therapeutics sees a net positive catalyst from the FDA acceptance of its TYVASO application for IPF, though this is partially offset by a delay in the SMI filing. The specific target of 10,000 patients at launch provides a concrete revenue growth target for Q2 2027.
- UTHR+0.30
No priced-in read yet





